Literature DB >> 3580855

Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory task.

W S Messer, G J Thomas, W Hoss.   

Abstract

The behavioral effects of the two muscarinic antagonists scopolamine and pirenzepine were examined using a representational memory task for rats in a T-maze. Rats were pretrained to a criterion of 100% correct responses for daily sessions of 10 paired-run trials. The training procedures eliminated all neophobic or wary responses, and response times were invariably short (less than 3 s). Following the initial training sessions, guide cannulae were surgically implanted bilaterally over the hippocampus of each animal. Following recovery from surgery, animals were injected with saline (0.5 microliter to each hippocampus), scopolamine hydrobromide (0.5 microliter of a 60 mg/ml solution (30 micrograms) to each side), or pirenzepine (0.5 microliter of a 69.1 mg/ml solution (34.6 micrograms) to each side) according to a fixed schedule. Saline injections aimed between the blades of the dorsal dentate gyrus failed to produce any change in the performance of the memory task. Initial doses of scopolamine, applied to the same area, produced a decrease in the percentage of correct responses as did the initial dose of pirenzepine. In contrast to pirenzepine, scopolamine also produced increases in response times even to the point of defaulted trials (response times greater than 90 s) in some animals following drug injections. Saline injections failed to produce significant impairments on the days following scopolamine injections, although animals receiving pirenzepine injections were still impaired on the two days immediately following the initial pirenzepine injection. Subsequent doses of pirenzepine were ineffective in producing an impairment of performance while scopolamine injections were less effective than the initial dose.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580855     DOI: 10.1016/0006-8993(87)91217-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  The effect of sevoflurane on the expression of M1 acetylcholine receptor in the hippocampus and cognitive function of aged rats.

Authors:  Sheng Peng; Yan Zhang; Guo-Jun Li; Deng-Xin Zhang; Da-Peng Sun; Qiang Fang
Journal:  Mol Cell Biochem       Date:  2011-10-14       Impact factor: 3.396

Review 3.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.

Authors:  A I Levey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 4.  The use of null mutant mice to study complex learning and memory processes.

Authors:  J M Wehner; B J Bowers; R Paylor
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

5.  A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment.

Authors:  Inge Klinkenberg; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

6.  Effects of intra-hippocampal scopolamine injections in a repeated spatial acquisition task in the rat.

Authors:  A Blokland; W Honig; W G Raaijmakers
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems.

Authors:  Soheil Keihan Falsafi; Alev Deli; Harald Höger; Arnold Pollak; Gert Lubec
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.